الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 98 |  |  |
| | | from | 98 | | |
Abstract
Hepatitis C virus (HCV)-induced cirrhosis is a consequence of the infection’s ongoing liver injury. Cirrhotic individuals are more prone to develop bleeding, particularly gastrointestinal bleeding, due to portal hypertension and/or coagulopathy brought on by liver synthesis failure. On the other hand, ironically, they also run the danger of thrombosis, predominantly in the splanchnic circulation, especially when platelet counts are increased by transfusion or medication.
Direct-acting antivirals (DAAs) treatment in HCV-related cirrhotic patients is associated with significant modifications in thrombin generation, possibly correcting hypercoagulability, due to their high sustained virologic response (SVR) rate and outstanding tolerability.
The present research aimed to investigate the hypercoagulability in individuals with HCV-related cirrhosis both before and after therapy using standard global and individual-factor coagulation assays.
The total number of participants in this prospective trial was 43. They were divided into two groups: the patients group, which included 25 patients with HCV-related cirrhosis before beginning DAA therapy and after recovery, was made up of individuals with ages ranging from 24 to 77. The means and standard deviations of this group were 48.8 and 13.6, respectively. They were chosen and assessed for eligibility in the Clinical Pathology Departments, an outpatient clinic for the Hepatology department at Minia University Hospital. 18 healthy adults with ages ranging from 28 to 70 and means and SDs of 46.8 to 13.7 were chosen for an age- and sex-matched control group.
The current findings showed:
The patient group’s platelet count (before to treatment) declined statistically considerably when compared to the control group, although there were no discernible changes in the hemoglobin, TLC, or RBC levels.
The patient group’s ALT and AST enzyme levels increased statistically significantly before therapy as compared to the control group.
In contrast to the control group, the patient group’s pre-treatment prothrombin time (PT) and INR increased statistically significantly, while the pre-treatment PT% activity test of the patient group decreased statistically significantly compared to the control group and the pre-treatment activated partial thromboplastin time (APTT) test did not differ statistically significantly from the control group.
The TAT and F1+2 tests showed a statistically significant increase when comparing the patient group before treatment to the control group, but the protein C level did not show a statistically significant difference between the patient group before treatment and the control group (P value > 0.05).
When compared to the patient group prior to therapy, there was a statistically significant rise in the proportion of active PT tests in the patient group, but there was no statistically significant change in the INR test. However, as compared to the patient group before to therapy, there was a statistically significant decline in the patient group’s PT test, APTT test, TAT test, and F1+2 test results (P value 0.001).
There was no noticeable difference between the Protein C test outcomes before and after the therapy (P value > 0.05).